Cancer Centers Must Promote Culture in Support of Reimbursement for Clinical Trials

Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

At the ACCC 40th Annual National Meeting, David Evans, RN, MSN, MBA, discussed some of the top reimbursement issues that cancer centers face when it some to clinical trials.

At the ACCC 40th Annual National Meeting, David Evans, RN, MSN, MBA, discussed some of the top reimbursement issues that cancer centers face when it some to clinical trials. Evans says that an organization that is committed to offering clinical trials as treatment options should have, or needs to develop, a culture and infrastructure that promotes enrollments, supports patients in dealing with third-party payers, and challenges anyone who threatens to withhold reimbursement for the routine cost of cancer care.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
Data highlight that patients who are in Black and poor majority areas are less likely to receive liver ablation or colorectal liver metastasis in surgical cancer care.
Findings highlight how systemic issues may impact disparities in outcomes following surgery for patients with cancer, according to Muhammad Talha Waheed, MD.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Related Content
Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

BCR Seen With Apalutamide Combo in Entire High-Risk Prostate Cancer Cohort

May 5th 2024
Article

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy

January 1st 2024
Podcast

Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

18F-PSMA-1007 PET/CT Improves Staging Vs MRI in Prostate Cancer

May 3rd 2024
Article

Findings support the use of 18F-PSMA-1007 PET/CT in the preoperative workflow of intermediate- and high-risk prostate cancer.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Head and neck cancer

Early Intervention, Regular Assessment Can Grasp Symptom Course for Head and Neck Cancer Therapy

April 28th 2024
Article

Nurses must increase the frequency of their assessments for early intervention of patients who undergo treatment for their head and neck cancer, in an effort to truly individualized care.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Elderly Cancer Populations Have Inconsistent Symptom Burden/Clusters

April 26th 2024
Article

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.